Replies to post #187116 on Biotech Values

[DewDiligence]

OHRP misses primary endpoint in phase-2 AMD study:

http://in.reuters.com/article/2015/03/27/us-ohr-study-idINKBN0MN1AO20150327

This shouldn’t be a surprise. Squalamine is a raw molecule from nature that was never subjected to any chemical optimization. It’s a weak anti-angiogenesis agent when administered systemically, and reformulating it as an eye drop (as OHRP has done) doesn’t eliminate these shortcomings.

OHRP’s own PR:
http://finance.yahoo.com/news/ohr-pharmaceutical-announces-final-topline-110000443.html